These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22440948)

  • 21. Is tumor response important for renal carcinoma?
    Inman BA; George DJ
    Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
    [No Abstract]   [Full Text] [Related]  

  • 22. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
    Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
    Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.
    Procopio G; Verzoni E; Iacovelli R; Guadalupi V; Gelsomino F; Buzzoni R
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1631-40. PubMed ID: 22050012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
    Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
    Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
    Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
    Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
    Bukowski RM
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):25-8. PubMed ID: 16773842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicities of targeted therapy and their management in kidney cancer.
    Di Lorenzo G; Porta C; Bellmunt J; Sternberg C; Kirkali Z; Staehler M; Joniau S; Montorsi F; Buonerba C
    Eur Urol; 2011 Apr; 59(4):526-40. PubMed ID: 21277078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal cell carcinoma: molecularly targeted therapy.
    Cáceres W; Cruz-Chacón A
    P R Health Sci J; 2011 Jun; 30(2):73-7. PubMed ID: 21682150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.
    Neuzillet Y; Culine S; Patard JJ
    Int J Urol; 2009 Nov; 16(11):855-61. PubMed ID: 19674168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal cell carcinoma.
    Rathmell WK; Martz CA; Rini BI
    Curr Opin Oncol; 2007 May; 19(3):234-40. PubMed ID: 17414642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma.
    Ravaud A; Gross-Goupil M
    Cancer Treat Rev; 2012 Dec; 38(8):996-1003. PubMed ID: 22330762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Harshman LC; Srinivas S
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
    Tan TH; Pranavan G; Haxhimolla HZ; Yip D
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
    Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Axitinib in the treatment of metastatic renal cell carcinoma.
    Ho TH; Jonasch E
    Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
    Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
    Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Targeted treatment of renal cell carcinoma, treatment caused side-effects and side-effect management].
    Nagyiványi K; Géczi L
    Orv Hetil; 2017 Sep; 158(38):1488-1502. PubMed ID: 28920717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and future systemic treatments for renal cell carcinoma.
    Fisher R; Gore M; Larkin J
    Semin Cancer Biol; 2013 Feb; 23(1):38-45. PubMed ID: 22705280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.